Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 1.00 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.55 |
| ▸ | KDR | P35968 | 6/20 | 0.54 |
| ▸ | FLT1 | P17948 | 5/20 | 0.54 |
| ▸ | FLT4 | P35916 | 5/20 | 0.54 |
| ▸ | SIRT7 | Q9NRC8 | 1/20 | 0.54 |
| ▸ | VCP | P55072 | 3/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180361 | 0.89 | DGAT1 (0.81) | DGAT1KDRFLT1FLT4SIRT7 | |
| SCHEMBL180503 | 0.87 | DGAT1 (0.76) | DGAT1FFAR1KDRFLT1FLT4 | |
| SCHEMBL180699 | 0.78 | DGAT1 (0.64) | DGAT1KDRFLT1FLT4SIRT7 | |
| SCHEMBL180696 | 0.78 | DGAT1 (0.64) | DGAT1KDRFLT1FLT4SIRT7 | |
| SCHEMBL16546763 | 0.78 | DGAT1 (0.63) | DGAT1KDRFLT1FLT4SIRT7 | |
| SCHEMBL180392 | 0.78 | DGAT1 (0.63) | DGAT1KDRFLT1FLT4SIRT7 | |
| SCHEMBL14617024 | 0.78 | DGAT1 (0.63) | DGAT1KDRFLT1FLT4SIRT7 | |
| SCHEMBL180766 | 0.77 | SIRT7 (0.65) | DGAT1KDRFLT1FLT4SIRT7 | |
| SCHEMBL180428 | 0.77 | DGAT1 (1.00) | DGAT1KDRFLT1FLT4SIRT7 | |
| SCHEMBL16546760 | 0.77 | DGAT1 (0.64) | DGAT1KDRFLT1FLT4SIRT7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2404905-A1 | New compounds | Novartis AG (CH) | 2012-01-11 | — | — | EP | claimed |
| EP-2402320-A1 | Anorectic agents | Novartis AG (CH) | 2012-01-04 | — | — | EP | claimed |
| EP-2301923-A1 | New compounds | Novartis AG (CH) | 2011-03-30 | — | — | EP | claimed |
| US-20150065517-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-8912208-B2 | (4-{4-[5-(benzooxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid useful for treating or preventing conditions or disorders associated with DGAT1 activity | NOVARTIS AG (CH) | 2014-12-16 | — | — | US | disclosed |
| EP-2418202-B1 | (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors | NOVARTIS AG (CH) | 2014-01-29 | — | — | EP | disclosed |
| US-20130018054-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
| US-20130018074-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
| EP-2418202-A1 | New compounds | Novartis AG (CH) | 2012-02-15 | — | — | EP | disclosed |
| EP-2404905-A1 | New compounds | Novartis AG (CH) | 2012-01-11 | — | — | EP | disclosed |
| EP-2402319-A1 | DGAT Inhibitors | Novartis AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402320-A1 | Anorectic agents | Novartis AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402318-A1 | DGAT inhibitors | Novartis AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402317-A1 | DGAT inhibitor | Novartis AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2301923-A1 | New compounds | Novartis AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-20100016387-A1 | METHOD OF TREATMENT | BOSE AVIRUP | 2010-01-21 | — | — | US | disclosed |
| EP-2101783-A2 | METHOD OF PREVENTING OR TREATING MYOCARDIAL ISCHEMIA | Novartis Ag (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2009112445-A1 | METHOD OF INCREASING CELLULAR PHOSPHATIDYL CHOLINE BY DGAT1 INHIBITION | NOVARTIS AG (CH) | 2009-09-17 | — | — | WO | disclosed |
| WO-2008073865-A2 | METHOD OF PREVENTING OR TREATING MYOCARDIAL ISCHEMIA | NOVARTIS AG (CH) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065517-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | DGAT1 1/4885FFAR1 1204/4885KDR 4520/4885 |
| US-20100016387-A1 | METHOD OF TREATMENT | DGAT1, DGAT2, DGKA | DGAT1 1/4885FFAR1 848/4885KDR 3874/4885 |
| US-20130018054-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | DGAT1 1/4885FFAR1 1234/4885KDR 4537/4885 |
| US-20130018074-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | DGAT1 1/4885FFAR1 1234/4885KDR 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.